- Net Ingrezza product sales forecast for 2025 is between $2.50 billion to $2.60 billion, missing the estimate of $2.65 billion.
- Research and development (R&D) expenses are projected to range from $960 million to $1.01 billion, which is higher than the estimated $863.1 million.
- Sales, General, and Administrative (SG&A) expenses are anticipated to be between $1.11 billion to $1.13 billion, surpassing the estimate of $1.1 billion.
- Fourth-quarter revenue reached $627.7 million, marking a 22% year-over-year increase, though slightly below the estimate of $629.2 million.
- Collaboration revenue decreased by 19% year-over-year to $6.5 million, but exceeded the estimate of $5.05 million.
- Fourth-quarter R&D expenses were $185.6 million, a 35% increase year-over-year, higher than the estimated $169.8 million.
- SG&A expenses for the fourth quarter rose by 31% year-over-year to $287.8 million, above the estimate of $260 million.
- Adjusted earnings per share (EPS) for the fourth quarter were $1.69, compared to $1.54 the previous year, missing the estimate of $1.90.
- Analyst ratings are: 21 buys, 4 holds, and 0 sells.
Neurocrine Biosciences on Smartkarma
On Smartkarma, analyst coverage of Neurocrine Biosciences by Baptista Research is optimistic. In the report “Neurocrine Biosciences: Commercial Expansion & Market Penetration Underpinning Our ‘Outperform’ Rating! – Major Drivers,” CEO Kyle Gano’s leadership is highlighted for strengthening the company’s position in neuroscience. Revenue growth has been significant, notably driven by the drug INGREZZA, with $613 million in sales this quarter, a 25% year-over-year increase.
In another report titled “Neurocrine Biosciences: Recent Innovations & Strategic Commercial Preparations for Crinecerfont Driving Our Optimism! – Major Drivers,” the focus is on strategic movements and achievements in 2024. Despite challenges common to biotech firms, CEO Kevin Gorman’s tenure saw strong financial and clinical progress. Baptista Research conducts a thorough analysis to assess factors influencing the company’s value in the market, using a Discounted Cash Flow methodology for an independent valuation.
A look at Neurocrine Biosciences Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to Smartkarma Smart Scores, Neurocrine Biosciences shows promising signs for long-term growth in the pharmaceutical industry. With a strong momentum score of 5, the company is demonstrating positive performance trends that could translate into continued success. Additionally, its resilience score of 4 indicates a robust ability to overcome challenges, ensuring a steady path towards achieving its goals. While the dividend score is lower at 1, suggesting limited payouts to shareholders, the value score of 2 highlights a balance between the company’s current worth and its potential for future value appreciation. With a growth score of 3, Neurocrine Biosciences is positioned for expansion and innovation in the field of neuro therapeutic development.
Neurocrine Biosciences, Inc. is a biopharmaceutical company dedicated to advancing treatments for various neurological and psychiatric conditions. Specializing in neuropsychiatric, neuroinflammatory, and neurodegenerative disorders, the company’s research and development efforts target a wide range of illnesses, including anxiety, depression, Alzheimer’s disease, insomnia, and more. By focusing on innovative therapeutic interventions for complex conditions like malignant brain tumors, multiple sclerosis, obesity, and diabetes, Neurocrine Biosciences aims to make a significant impact on improving the quality of life for patients. With a balanced approach towards value, growth, and resilience, the company is poised for long-term success in addressing critical unmet medical needs.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
